Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.

Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.

Abstract: The present invention pertains to methods of determining where, on the skin, a diagnostic, therapeutic, or cosmetic agent is likely to be most effectively applied (e.g., injected), and to methods for monitoring a patient after such an agent has been administered. The monitoring can produce information useful in determining whether a diagnostic, therapeutic (e.g., surgical), or cosmetic regime should be initiated, continued, continued in a modified fashion, or terminated (e.g., for a brief or prolonged period of time). The methods can be repeated periodically and use a non-invasive, in vivo form of digital image speckle correlation (DISC) to track deformation of the skin.

Abstract: The present invention pertains to methods of determining where, on the skin, a diagnostic, therapeutic, or cosmetic agent is likely to be most effectively applied (e.g., injected), and to methods for monitoring a patient after such an agent has been administered. The monitoring can produce information useful in determining whether a diagnostic, therapeutic (e.g., surgical), or cosmetic regime should be initiated, continued, continued in a modified fashion, or terminated (e.g., for a brief or prolonged period of time). The methods can be repeated periodically and use a non-invasive, in vivo form of digital image speckle correlation (DISC) to track deformation of the skin.

Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.

Abstract: The present invention features, inter alia, biocompatible compositions that include a poloxamer and one or more additives such as hyaluronic acid, gelatin, fibronectin, or a peptide fragment of fibronectin. The compositions are useful in tissue repair or remodeling, including repair of an injured spinal disc, in drug delivery, in cell culture, and in inhibiting the formation of adhesions.

Abstract: The present invention pertains to methods of determining where, on the skin, a diagnostic, therapeutic, or cosmetic agent is likely to be most effectively applied (e.g., injected), and to methods for monitoring a patient after such an agent has been administered. The monitoring can produce information useful in determining whether a diagnostic, therapeutic (e.g., surgical), or cosmetic regime should be initiated, continued, continued in a modified fashion, or terminated (e.g., for a brief or prolonged period of time). The methods can be repeated periodically and use a non-invasive, in vivo form of digital image speckle correlation (DISC) to track deformation of the skin.

Abstract: The present invention features, inter alia, biocompatible compositions that include a poloxamer and one or more additives such as hyaluronic acid, gelatin, fibronectin, or a peptide fragment of fibronectin. The compositions are useful in tissue repair or remodeling, including repair of an injured spinal disc, in drug delivery, in cell culture, and in inhibiting the formation of adhesions.

Abstract: A HA-gelatin-pluronic hydrogel and a method for making a HA-gelatin-pluronic hydrogel are provided. The hydrogel includes hyaluronic acid, gelatin-Type A and a thermoreversible, hydrophilic non-ionic surfactant gel. The thermoreversible, hydrophilic non-ionic surfactant gel can be a poly(ethylene oxide)99-poly(propylene oxide)67-poly(ethylene oxide)99 (“Pluronic F127”). The weight ratio of HA to gelatin-Type A is between 1:2 and 2:1 and preferably about 1:1. The weight ratio of HA and gelatin-Type A to thermoreversible, hydrophilic non-ionic surfactant gel is between 1:3,000 and 1:150, preferably between 1:3,000 and 1:600 and most preferably about 1:2,400. The hydrogel is formed by combining hyaluronic acid and gelatin-Type A to form a solution, cooling the solution, mixing the solution with Pluronic F127 to form a mixture and storing the mixture at a temperature of from 25° C. to 45° C. preferably about 37° C.

Abstract: The present invention pertains to methods of determining where, on the skin, a diagnostic, therapeutic, or cosmetic agent is likely to be most effectively applied (e.g., injected), and to methods for monitoring a patient after such an agent has been administered. The monitoring can produce information useful in determining whether a diagnostic, therapeutic (e.g., surgical), or cosmetic regime should be initiated, continued, continued in a modified fashion, or terminated (e.g., for a brief or prolonged period of time). The methods can be repeated periodically and use a non-invasive, in vivo form of digital image speckle correlation (DISC) to track deformation of the skin.

Abstract: Hydrogels formed from hyaluronic acid, a nanoclay and gelatin-type A. The hyaluronic acid is preferably dissolved in a cell culture medium containing amino acids, salts, glucose, vitamins and an antibiotic to form a hyaluronic acid solution. The gelatin-type A has a weight/volume of from about 0.02% to 0.08%. The nanoclay is exfoliated in deionized water and preferably includes SiO2, MgO, Na2O and Li2O.

Abstract: Hydrogels formed from hyaluronic acid, a nanoclay and gelatin-type A. The hyaluronic acid is preferably dissolved in a cell culture medium containing amino acids, salts, glucose, vitamins and an antibiotic to form a hyaluronic acid solution. The gelatin-type A has a weight/volume of from about 0.02% to 0.08%. The nanoclay is exfoliated in deionized water and preferably includes SiO2, MgO, Na2O and Li2O.